Hap Trading, LLC Lexicon Pharmaceuticals, Inc. Call Options Transaction History

Hap Trading, LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2021 Nov 10, 2021	BUY	$3.38 - $5.35 $2,366 - $3,744	700 Added 5.69%	13,000 $4,000
Q2 2021 Aug 11, 2021	SELL	$4.12 - $5.87 $154,088 - $219,538	-37,400 Reduced 75.25%	12,300 $11,000
Q1 2021 May 14, 2021	SELL	$3.45 - $9.09 $104,535 - $275,427	-30,300 Reduced 37.88%	49,700 $97,000
Q4 2020 Feb 16, 2021	BUY	$1.05 - $3.67 $70,140 - $245,156	66,800 Added 506.06%	80,000 $81,000
Q3 2020 Nov 13, 2020	BUY	$1.44 - $2.1 $19,008 - $27,720	13,200 New	13,200 $2,000
Q2 2020 Aug 10, 2020	SELL	$1.75 - $2.3 $58,625 - $77,050	-33,500 Closed	0 $0
Q1 2020 May 08, 2020	SELL	$1.8 - $4.28 $5,220 - $12,412	-2,900 Reduced 7.97%	33,500 $1,000
Q4 2019 Feb 11, 2020	SELL	$3.16 - $5.15 $11,060 - $18,025	-3,500 Reduced 8.77%	36,400 $30,000
Q3 2019 Nov 12, 2019	BUY	$1.2 - $6.66 $25,080 - $139,194	20,900 Added 110.0%	39,900 $17,000
Q2 2019 Aug 14, 2019	BUY	$5.35 - $7.11 $36,915 - $49,059	6,900 Added 57.02%	19,000 $5,000
Q1 2019 May 10, 2019	BUY	$4.36 - $7.94 $52,756 - $96,074	12,100 New	12,100 $2,000

141

238M

459K

133K

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $134M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.